Firstly this paper analyses the related regulations formulated by the foreign government, such as FDA, USA; contrasting with the characteristics of Traditional Chinese Medicine (TCM), and puts forth the argument that the international market development strategy for TCM should follow the principle of beginning with dietary supplements, through the food for special dietary uses and finally declaring as OTC drugs after the gradual transition from NDA of more mature drugs on the market. The correlated scientific and technological support on systems biology should be that base on the classification of clinic phenotype to setup of the quality-guarantee system and the application standard aiming at symptoms relief for achieving safety and efficacy. The information processing platform on systems biology with its functional units is introduced as a scientific and technical tool to support the international market development of TCM.
展开▼
